share_log

Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM維持對Champions Oncology的買入,將目標價下調至7.5美元
Benzinga ·  2023/09/22 11:40

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

Roth MKM分析師Scott Henry維持冠軍腫瘤學(納斯達克:CSBR)的Buy,並將目標價從9美元下調至7.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論